Senza HFX iQ System
Nevro Corporation · Decision date Aug 15, 2025
What did the FDA approve?
FDA records P130022/S067 as a supplement to PMA P130022, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 15, 2025.
FDA approval order statement
Approval for changes to the printed circuit board assembly (PCBA) board used in IPG3000, including replacing the microcontroller from rev 2 to rev 3, replacing the fuel gauge with a battery voltage measurement circuit, changing the material of the printed circuit board (PCB), moving the PCBA battery fuse from the negative terminal to the positive terminal, other minor modifications to PCB layout (reorganizing components and modification of solder pad size), as well as an alternate PCBA supplier for IPG3000.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Neurology
- Decision date
- Aug 15, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P130022/S067
- Regulatory pathway
- PMA supplement
- Applicant
- Nevro Corporation
- Product code
- LGW
- Decision code
- APPR
- Decision date
- Aug 15, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Nevro Corporation
- Product code
- LGW
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P130022/S067 received
Application receipt date recorded by FDA.
P130022/S067 · FDA decision
Normal 180 Day Track
P130022/S069 · Related supplement
HFX Dynamis System
Timeline entries are records held by MedtechLedger for P130022. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130022
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
HFX Dynamis SystemP130022/S069 | Nevro Corporation | PMA supplement | Aug 18, 2026 | FDA |
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Nevro Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1800 Bridge Pkwy., Redwood City, CA, 94065
Sources and methodology
- Original FDA record: P130022/S067
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




